ULTRAGENYX PHARMACEUTICAL INC. Increase (Decrease) in Other Operating Assets
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Increase (Decrease) in Other Operating Assets of -$12.27 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2024-11-06
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in other operating assets for the quarter ending 2024-09-30 was -$12.72M.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in other operating assets for the quarter ending 2024-06-30 was $7.00M.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in other operating assets for the quarter ending 2024-03-31 was -$6.55M, a 1362.62% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in other operating assets for the quarter ending 2023-12-31 was $1.26M.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in other operating assets for fiscal 2023 was -$15.32M.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in other operating assets for fiscal 2022 was -$3.80M, a 112.87% decline from fiscal 2021.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in other operating assets for fiscal 2021 was $29.51M.
| Period end | Increase (Decrease) in Other Operating Assets 3 month | Increase (Decrease) in Other Operating Assets 6 month | Increase (Decrease) in Other Operating Assets 9 month | Increase (Decrease) in Other Operating Assets 12 month | Increase (Decrease) in Other Operating Assets 47 month |
|---|---|---|---|---|---|
| 2024-09-30 | -$12.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$5.72M derived: sum of 2 quarters · filed 2024-11-06 | -$12.27M 10-Q · filed 2024-11-06 | -$11.01M derived: sum of 4 quarters · filed 2024-11-06 | |
| 2024-06-30 | $7.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $449.00K 10-Q · filed 2024-08-02 | $1.71M derived: sum of 3 quarters · filed 2024-08-02 | -$3.28M derived: sum of 4 quarters · filed 2024-11-06 | |
| 2024-03-31 | -$6.55M 10-Q · filed 2024-05-03 | -$5.29M derived: sum of 2 quarters · filed 2024-05-03 | -$10.28M derived: sum of 3 quarters · filed 2024-11-06 | -$22.40M derived: sum of 4 quarters · filed 2024-11-06 | |
| 2023-12-31 | $1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | -$3.73M derived: sum of 2 quarters · filed 2024-11-06 | -$15.84M derived: sum of 3 quarters · filed 2024-11-06 | -$15.32M 10-K · filed 2024-02-21 | |
| 2023-09-30 | -$4.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$17.10M derived: sum of 2 quarters · filed 2024-11-06 | -$16.58M 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | -$12.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | -$11.59M 10-Q · filed 2024-08-02 | |||
| 2023-03-31 | $519.00K 10-Q · filed 2024-05-03 | ||||
| 2022-12-31 | -$3.80M 10-K · filed 2024-02-21 | ||||
| 2021-12-31 | $29.51M 10-K · filed 2024-02-21 | ||||
| 2014-06-30 | $579.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | -$1.52M 10-Q · filed 2014-08-11 | |||
| 2014-03-31 | -$2.10M 10-Q · filed 2014-05-12 | $550.00K 10-Q · filed 2014-05-12 | |||
| 2013-06-30 | $33.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $129.00K 10-Q · filed 2014-08-11 | |||
| 2013-03-31 | $96.00K 10-Q · filed 2014-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |